Document:

License Agreement

  
 Exhibit 10.8

  
 **CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM
THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 LICENSE AGREEMENT 
  
 THIS LICENSE AGREEMENT (“Agreement”) dated as of April 27, 2004 (“Effective Date”), is entered into between MediciNova, Inc., a
Delaware corporation (“MN”) having a place of business located at 4350 La Jolla Village Drive, Ste 950, San Diego, California 92122, U.S.A., and Mitsubishi Pharma Corporation, a Japanese corporation (“MPC”), having a place of
business located at 6-9, Hiranomach 2-chome, Chuo-ku, Osaka 541-0046, Japan. 
  
 W I T N E S S E T H: 
  
 WHEREAS,
MPC is the owner of the MPC Intellectual Property, as defined herein; 
  
 WHEREAS, MN desires to obtain an exclusive license, with a right to grant sublicenses, under the MPC Intellectual Property, and MPC desires to grant such license to MN, upon the terms and conditions set forth herein; 
  
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual
covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
  
 ARTICLE 1 
 DEFINITIONS 
  
 For purposes of this Agreement, unless
specifically set forth to the contrary herein, the terms defined in this Article 1 shall have the respective meanings set forth below, it being understood that words in the singular include the plural and vice versa: 
  
 1.1 “Act” shall mean the United States Food Drug and
Cosmetic Act of 1938, as amended, and the rules and regulations promulgated thereunder, or any successor act, as the same shall be in effect from time to time. 
  

1.2 “Affiliate” shall mean, (i) any corporation or business entity of which at least fifty percent (50%) of the securities or other
ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by a Party or by any entity mentioned in (ii) hereinafter; or (ii) any corporation or business
entity which, directly or indirectly, owns, controls or holds at least fifty percent (50%) (or the 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 
maximum ownership interest permitted by law) of the securities or other ownership interests representing the equity, voting stock or general partnership
interest of a Party. 
  
 1.3 “API” shall mean
Compound, in bulk form, for use as the active pharmaceutical ingredient in the manufacture of Products. 
  
 1.4 “Business Day(s)” shall mean any day that is not a Saturday, a Sunday, a national holiday in Japan and/or United States, a day on
which the New York Stock Exchange and/or the Tokyo Stock Exchange is closed. 
  
 1.5 “Calendar Quarter” shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31. 
  
 1.6 “Calendar Year” shall mean each successive period of
twelve (12) months commencing on January 1 and ending on December 31. 
  
 1.7 “CFR” shall mean the United States Code of Federal Regulations. 
  
 1.8 “cGMP” shall mean current good manufacturing practices as defined in regulations promulgated by the FDA under the Act and, if applicable, corresponding applicable laws and regulations of other
countries in the MN Territory or the MPC Territory relating to the formulation, manufacture, testing prior to delivery, storage and delivery of the Compound and Product. 
  
 1.9 “Claimed Compound” shall mean a compound, other than Compound, which is disclosed or claimed in U.S.
Patent No. 5,234,948. 
  
 1.10 “Compound” shall
mean the chemical compound known as [**] and designated [**], as diagrammed on Schedule 1.10 hereto, and [**]. 
  
 1.11 “Control” shall mean possession of the ability to grant a license or sublicense as provided for herein without violating the terms
of any agreement with any Third Party. 
  
 1.12 “Cost of
Goods Sold” shall mean all costs incurred by MPC or MN associated with the manufacturing of API or Product, as applicable depending on the context, that are considered costs of goods sold in accordance with GAAP, including labor, materials
and factory costs, including amounts payable to third party contractors and manufacturers. 
  
 1.13 “EMEA” shall mean the European Agency for the Evaluation of Medicinal Products based in London (UK), as established by Council Regulation n° 2309/93 of July 22, 1993, as subsequently amended
by Commission Regulation 649/98 of March 23, 1998, and any successor thereto having substantially the same functions. 
  
 1.14 “End of Phase 2 Meeting” shall mean the first end of Phase 2 meeting with the FDA, as defined in 21 CFR Section 312.47, intended to
determine the safety of proceeding to 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 2 

 
Phase 3, evaluate the Phase 3 plan and protocols and identify any additional information necessary to support an NDA for Product. 
  
 1.15 “EXW” shall have the meaning as such term is defined in
the ICC Incoterms, 2000, International Rules for the Interpretation of Trade Terms, ICC Publication No. 560. 
  
 1.16 “FDA” shall mean the United States Food and Drug Administration and any successor thereto having substantially the same functions.

  
 1.17 “Field” shall mean any use of Compound
or Product in the prophylaxis, palliation, diagnosis or treatment of any human disease. 
  
 1.18 “First Commercial Sale” shall mean the first commercial sale of Product to a Third Party in each country in the MN Territory by MN, its Affiliates and/or its sublicensees after Regulatory
Approval has been granted by the Regulatory Authority of such country. 
  
 1.19 “GAAP” shall mean generally accepted accounting principles in the United States. 
  
 1.20 “Generic Competition” shall mean the situation, in any particular country in the MN Territory, that (i) any Generic Drug is sold in
the Field in a such country in the MN Territory and despite MN’s commercially reasonable efforts to commercialize the Product pursuant to Section 2.1.4 (ii) Generic Drug(s) achieve a market share in [**] or greater of the total
prescriptions for Product in such country (as so shown by the average of the monthly IMS (or IMS-equivalent) data for such prescriptions) or (iii) in jurisdictions in which no IMS or IMS equivalent data is available, the Net Sales in two consecutive
Calendar Quarters immediately or at any time after the launch of a Generic Drug in such jurisdiction falls to [**] or below of the Net Sales in the two consecutive Calendar Quarters immediately prior to the launch of such Generic Drug in such
jurisdiction. 
  
 1.21 “Generic Drug(s)” shall
mean any product containing Compound for which Regulatory Approval for the same indication(s) as that of the Product is obtained by abbreviated NDA (ANDA) in the United States or a corresponding application in any country other than United States in
the MN Territory; in each case other than a product introduced in such country by MN, its Affiliates or sublicensees. 
  
 1.22 “Improvement” shall mean any improvement, including without limitation any change or modification to any method, process,
composition any enhancement in the manufacture, formulation, ingredients, preparation, presentation, means of delivery, dosage or packaging relating to Compound or Product. 
  
 1.23 “IND” shall mean an investigational new drug application, as defined in 21 CFR Section 312.3, and any
amendments thereto, filed with the FDA or an equivalent application filed with an equivalent Regulatory Authority outside the United States, the filing of which is necessary to commence clinical testing of Product in such regulatory jurisdiction.

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 3 

 1.24 “Major European Countries” shall mean United Kingdom, France, Germany or Italy.

  
 1.25 “Marketing Approval Application” or
“MAA” shall mean any new registration application or marketing authorization application, including any supplements or amendments thereto, such as a foreign counterpart or comparable to the NDA, which MN may file with the requisite
Regulatory Authority in any jurisdiction in the MN Territory, that is required to obtain Regulatory Approval of Product for a particular indication in such jurisdiction. 
  
 1.26 “MN Intellectual Property” shall mean all intellectual property and proprietary rights in (i) all MN
Patent Assets and (ii) all MN Know-How. 
  
 1.27
“MN Know-How” shall mean any and all unpatented information and materials, including but not limited to, discoveries, Improvements, processes, formulae, data, inventions, invention disclosures, know-how and trade secrets, including
without limitation, all chemical, pharmaceutical, toxicological, biochemical, and biological, technical and nontechnical data, and information relating to the results of tests, assays, methods, and processes, and specifications and/or other
documents containing information and related data, and any preclinical, clinical, assay control, regulatory, and any other test results or information, that are necessary or useful for the development, manufacturing, Regulatory Approval and/or
marketing of Product and that become during the term of this Agreement owned or Controlled by MN. 
  
 1.28 “MN Patent Assets” shall mean all Patent Assets that are necessary or useful to develop, make, use, market, or sell Compound or
Product and that become during the term of this Agreement owned or Controlled by MN. 
  
 1.29 “MN Territory” shall mean all countries worldwide, except for the MPC Territory. 
  
 1.30 “MPC Intellectual Property” shall mean all intellectual property and proprietary rights in (i) all MPC Patent Assets and (ii) all
MPC Know-How. 
  
 1.31 “MPC Know-How” shall mean
any and all unpatented information and materials, including but not limited to, discoveries, Improvements, processes, formulae, data, inventions, invention disclosures, know-how and trade secrets, including without limitation, all chemical,
pharmaceutical, toxicological, biochemical, and biological, technical and nontechnical data, and information relating to the results of tests, assays, methods, and processes, and specifications and/or other documents containing information and
related data, and any preclinical, clinical, assay control, regulatory, and any other test results or information, that are necessary or useful for the development, manufacturing, Regulatory Approval and/or marketing of Compound or Product and that
are or become during the term of this Agreement owned or Controlled by MPC. 
  
 1.32 “MPC Licensee” shall mean a Third Party to which MPC licenses any or all MPC Intellectual Property in the MPC Territory in accordance with the terms of this Agreement. 
  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 4 

 1.33 “MPC Patent Assets” shall mean all Patent Assets that are necessary or useful to
develop, make, use, market, or sell Compound or Product and that are or become during the term of this Agreement owned or Controlled by MPC, including but not limited to the Patent Assets listed on Schedule 1.33 hereto, and any
counterparts thereof which have been or may be filed in other countries. 
  
 1.34 “MPC Territory” shall mean Japan, Singapore, Brunei, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Bangladesh, Pakistan, South Korea, People’s Republic of China and Taiwan.

  
 1.35 “NDA” shall mean a new drug application
as defined in the Act and applicable regulations promulgated thereunder that is submitted to the FDA to apply for Regulatory Approval of a Product in the United States and any amendments and supplements thereto. 
  
 1.36 “Net Sales” shall mean the sales revenues received by
MN or any MN Affiliate from sales of Products to Third Party customers, commencing upon the date of First Commercial Sale, after deducting, in accordance with GAAP, any (a) credits, allowances, samples, discounts and rebates to, and chargebacks from
the account of, such Third Party customers; (b) freight and insurance costs; (c) trade discounts, cash discounts, quantity discounts, rebates; (d)retroactive price reductions; (e) recalls, credits and allowances on account of returned or rejected
Product, including allowance for breakage or spoilage; (f) sales, value-added and other direct taxes incurred directly in connection with the sale of Product;(g) rebates, chargebacks or similar payments or credits granted to managed health
care organizations, wholesalers, distributors, buying groups, health care insurance carriers, pharmacy benefit management companies, health maintenance organizations, or other institutions or health care organizations or to any governmental or
regulatory authority in respect of any state, provincial, local or federal Medicare, Medicaid or similar programs in any country in the MN Territory; (h) write-offs for bad debts or allowances; and (i) customs duties, custom broker charges and other
surcharges and governmental charges incurred in connection with the exportation or importation of Product. 
  
 Sales or other transfers between MN and its Affiliates shall be excluded from the computation of Net Sales and no payments will be payable on such sales
or transfers except where such Affiliates are end users, but Net Sales shall include the subsequent sales to Third Parties by such Affiliates. 
  
 1.37 “Net Sublicense Consideration” shall mean (a) any amounts actually received by MN from sublicensees of the rights granted by MPC to
MN under Section 3.1 of this Agreement, as consideration or substantially similar to consideration for the grant of such sublicense, including but not limited to, as royalties based on net sales of Product by such sublicensee, as payments based on
the achievement of milestones relating to Product, or the amount of any profit of MN derived from the supply of API to sublicensee(s), (i.e. transfer price from MN to sublicensee(s) less Cost of Goods Sold borne by MN) (but specifically excluding
any amounts received by MN from sublicensees to fund or reimburse MN’s research and development costs incurred by MN in connection with the Product under such sublicense agreement between MN 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 5 

 
and its sublicensee)less (b) any amounts previously paid by MN to MPC under Sections 4.1 and 4.2 of this Agreement at or prior to the time MN receives such
payments from such sublicense. 
  
 1.38 “Party”
shall mean MPC or MN. 
  
 1.39 “Patent Assets”
means any patents, patent applications, certificates of invention, or applications for certificates of invention and any supplemental protection certificates, together with any extensions, registrations, confirmations, reissues, substitutions,
divisions, continuations or continuations-in-part, reexaminations or renewals thereof. 
  
 1.40 “Person” shall mean an individual, corporation, partnership, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated
organization, governmental authority or any other form of entity not specifically listed herein. 
  
 1.41 “Phase 2 Clinical Trial” shall mean clinical trials conducted in patients in accordance with current Good Clinical Practice and
designated to indicate (i) a statistically significant level of efficacy for the Product in the Field consistent with the clinical hypothesis set forth in the relevant protocol and (ii) the Product’s safety, as well as to obtain a preliminary
indication of the unit and/or dosage regimen required. 
  
 1.42
“Phase 3 Clinical Trial” shall mean a clinical trial conducted after an End of Phase 2 Meeting on a sufficient number of patients that is designed to establish that Product is safe and efficacious for its intended use, and to define
warnings, precautions and adverse reactions that are associated with Product in the dosage range to be prescribed, and supporting Regulatory Approval of Product in the Field. 
  
 1.43 “Product” shall mean any product, excluding an ophthalmic solution, in final form, packaged and
labeled for commercial sale by prescription, or by any other method (or, where the context so indicates, the product being tested in clinical trials), which contains Compound as the sole therapeutically active ingredient in any dosage form or
package configuration. 
  
 1.44 “Proprietary
Information” shall mean any and all scientific, clinical, regulatory, marketing, financial and commercial information or data, whether communicated in writing, orally or by any other means, which is owned and under the protection of one
Party and is being provided by that Party to the other Party in connection with this Agreement. 
  
 1.45 “Regulatory Approval” shall mean all approvals (including pricing and reimbursement approvals required for marketing authorization),
product and/or establishment licenses, registrations or authorizations of all regional, federal, state or local regulatory agencies, departments, bureaus or other Regulatory Authority, necessary for the manufacture, use, storage, import, export,
transport and sale of Compound or Product in a regulatory jurisdiction. 
  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 6 

 1.46 “Regulatory Authority” shall mean any court, tribunal, arbitrator, agency,
commission, official or other instrumentality of any federal, state, county, city or other political subdivision, domestic or foreign, that performs a function for such political subdivision similar to the function performed by the FDA for the
United States with regard to the approval, licensing, registration or authorization to test, manufacture, promote, market, distribute, use, store, import, transport or sell a product in the defined territory or political subdivisions, or with
respect to the approval of pricing or reimbursement for such product. 
  
 1.47 “Royalty Term” shall mean the period, on a country-by-country basis, that commences on the date of the First Commercial Sale in such country and expires ten (10)years from such date of First Commercial Sale in
such country. 
  
 1.48 “Royalty Year” shall mean,
(i) for the year in which the First Commercial Sale occurs (the “First Royalty Year”), the period commencing with the first day of the Calendar Quarter in which the First Commercial Sale occurs and expiring on the last day of the Calendar
Year in which the First Commercial Sale occurs; and (ii) for each subsequent year, each successive Calendar Year. 
  
 1.49 “Third Party” shall mean any Person other than MPC, MN and their respective Affiliates. 
  
 1.50 “Trademark” shall mean any trademark, trade name or
trade dress as MN shall adopt for Product that is at any time during the term of this Agreement owned or Controlled by MN. 
  
 1.51 “Valid Patent Claim” shall mean a claim of an issued and unexpired patent included within the MPC Patent Assets, which has not been
held revoked, or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, and which has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer or
otherwise. 
  
 ARTICLE 2 
 DEVELOPMENT; REGULATORY MATTERS; SUPPLY OF API 
  
 2.1 Development in the MN Territory. 
  
 2.1.1 Development Program. A summary of the development program relating to the Product proposed to be conducted by MN, its
Affiliate and/or a sublicensee (the “Program”) setting forth a summary of the planned activities is attached as Schedule 2.1, and may from time to time be amended by MN, its Affiliate and/or any sublicensee.

  
 2.1.2 Progress Reports. MN shall
annually and at any time upon MPC’s request, which is not more than once a year, provide MPC with a written report summarizing the status of all development activities of MN, its Affiliates and, if available to MN, sublicensees relating to
Product, including but not limited to, amendment of the Program, results of non-clinical and/or 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 7 

 
clinical studies conducted by MN, its Affiliates and/or, if available to MN, its sublicensees and MN’s activities relating to sublicenses to any Third
Party with the delivery to MPC of the summary of the annual report to an IND submitted by MN to the FDA in connection with the periodic reporting requirements of the IND to be in satisfaction of the foregoing requirement (the “Progress
Report”). 
  
 2.1.3 Study Protocol, IND
and NDA. MN, its Affiliate and/or its sublicensee shall, upon MPC’s request, provide MPC with the final version of the (i) study protocol of any clinical trials, (ii) IND and (iii) NDA. 
  
 2.1.4 Diligence. MN, its Affiliate and/or its
sublicensee shall use commercially reasonable efforts to develop and commercialize Product in the MN Territory in the Field, including the preparation and filing of regulatory submissions. As used herein, “commercially reasonable efforts”
shall mean efforts and resources normally used by MN for a product owned by it or to which it has exclusive rights, which is of similar market potential at a similar stage in its development or product life, taking into account issues of safety and
efficacy, product profile, the competitiveness of the marketplace, the proprietary position of the compound or product, the regulatory and reimbursement structure involved, the profitability of the applicable products, and other relevant factors.
The obligations of MN under this Agreement are expressly conditioned upon the absence of any adverse conditions relating to the safety or efficacy of Compound or Product including the absence of any action by any Regulatory Authority limiting the
development or commercialization of Compound or Product. 
  
 2.1.5 Remedies. Without prejudice to any remedies as provided in this Agreement and appropriate laws, in the event MN, its Affiliate or its sublicensee fails to meet any of the following events, and MN, its
Affiliate or its sublicensee does not demonstrate to MPC’s reasonable satisfaction that, despite MN’s, its Affiliate’s or its sublicensee’s efforts set forth in Section 2.1.4, the failure to meet the events was due to reason(s)
beyond MN’s, its Affiliate’s or sublicensee’s reasonable control, including, for example, (i) the unavailability of drug supplies needed to conduct the clinical trial, including, without limitation, as a result of failure of stability
or lack of a satisfactory formulation; (ii) an inability to conduct the clinical trial due to action on the part of any Regulatory Authority, including, without limitation, the placement of a clinical hold on such clinical trial; (iii) the conduct
of such clinical trial would violate any applicable laws, rules or regulations; or (iv) a good faith determination on the part of MN that the Product which is intended to be studied in the clinical trial is not safe or efficacious in its then
current formulation or dosage form or dose level, MPC shall have the right to terminate this Agreement: 
  

	 	(a)	[**]; or 

  

	 	(b)	[**]. 

  
 2.1.6 Regulatory Matters. MN shall own, control and retain primary legal responsibility for, and shall be responsible for funding,
the preparation, filing and prosecution of all filings and regulatory applications required to obtain Regulatory Approval of Product in the 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 8 

 
MN Territory in the Field. MN may subcontract portions of the Program; provided, however, that such subcontracted Third Party shall be subject to an
agreement with MN consistent with the confidentiality obligations in accordance with Article 7 below. MPC shall transfer free of charge to MN as soon as practicable after the Effective Date any IND or other regulatory filings or approvals in the MN
Territory relating to Compound or Product owned or Controlled by MPC and MPC shall allow MN or its designees free of charge the right to cross reference any IND, MAA or other regulatory filing in the MPC Territory or drug master file if owned or
Controlled by MPC and relating to Compound or Product. Upon MN’s reasonable request, MPC shall use commercially reasonable efforts to consult and cooperate with MN in obtaining Regulatory Approval of Product in the MN Territory. MN shall pay to
MPC (i) the actual cost incurred to MPC by such consultation and cooperation, including but not limited to travel expense and (ii) reasonable absence fee for MPC’s person dispatched to be separately agreed upon between the Parties. 

 
 2.2 Development in the MPC Territory. 
  
 2.2.1 Joint Committee. In case that at any time
during the term of this Agreement, MPC decides to develop Product in the MPC Territory for an indication that is the same as or substantially similar to any indication for which MN has developed or is developing Product in the MN Territory, MPC
shall so advise MN in writing and within thirty (30) days thereafter, the Parties shall establish a joint committee to coordinate, review and assess the clinical development of Product necessary to receive Regulatory Approvals, to harmonize
worldwide objectives for Product and to facilitate the transfer of data and regulatory communications, including the handling and reporting of adverse events, between the Parties. The specific composition, role and responsibility of the joint
committee, and details relating to meetings and decision making, shall be negotiated in good faith in an amendment to this agreement or a separate agreement to be entered into between the Parties at that time.  
  
 2.2.2 MPC shall own, control and retain primary legal
responsibility for, and shall be responsible for funding, the preparation, filing and prosecution of all filings and regulatory applications required to obtain Regulatory Approval of Product in the MPC Territory. 
  
 2.2.3 At MPC’s request and upon no less than ten (10)
months’ notice, MN agrees to supply or cause its Affiliate or its sublicensee supply to MPC with total requirements of API which is necessary for MPC’s development and commercialization of the Product. MN shall supply such API for
development at Cost of Goods Sold incurred by MN, its Affiliate or its sublicensee. Details of terms and conditions relating to the supply, including but not limited to the supply price of API for commercialization shall be negotiated in good faith
and agreed upon between the parties separately. 
  
 2.3 Supply
of API. MPC hereby agrees to supply to MN or its designees seventeen (17) kg of such API without any charge. MPC will ship such API, EXW at MPC’s facility, and MN shall bear the costs of shipment and insurance. The other delivery terms and
schedule for all such API shall be determined by mutual agreement of the parties, to be negotiated in good faith. 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 9 

 
In the event that MN or its Affiliate stops developing the Product, MN or its Affiliate shall prevent further use of such API and shall return to MPC or
destroy, pursuant to MPC’s decision, the remainder of such API. In the event that MN’s sublicensee halts development of the Product, MN shall use commercially reasonable efforts to preclude further use of any remaining API by such
sublicensee and to either secure the return of any such remaining API to MPC or have such remaining API destroyed. 
  
 2.4 Adverse Event Reporting. MPC, its Affiliate, and/or MPC Licensee and MN, its Affiliate and/or its sublicensee shall cooperate with respect to
the exchange of adverse event and safety information associated with the Compound and Product. Details of the cooperation in the handling of adverse event and safety information related to the Compound and Product shall be the subject of an
amendment to this agreement or a separate agreement to be negotiated in good faith between the Parties.  
  
 ARTICLE 3 
 LICENSES; SUBLICENSES 
  
 3.1 License Grant to MN. MPC hereby grants to MN and its Affiliate an
irrevocable, exclusive (even as to MPC) license under the MPC Intellectual Property, including the right to grant sublicenses, to practice the MPC Intellectual Property, and to develop, make, have made, use, offer for sale, market, sell, import, and
distribute Product into and throughout the MN Territory in the Field. Furthermore, MPC hereby grants to MN and its Affiliate a co-exclusive license with MPC under the MPC Intellectual Property, including the right to grant sublicenses, to make and
have made the Compound solely for the formulation anywhere in the world of Product intended for importation, marketing, distribution, use, offer for sale, and sale by each Party in each Party’s respective Territory, pursuant to Sections 2.1 and
2.2, above, provided that if either Party, its Affiliate, or its sublicensee desires to have a Third Party make the Compound at a site located within the other Party’s Territory, then such Party shall permit the other Party to submit a
competitive bid and consider in good faith the merits of such bid compared with other competitive bids received from one or more Third Parties. For the removal of doubt, MN’s co-exclusive right to make or have made Compound extends only to
Compound intended for Product to be marketed and sold in MN Territory and MPC’s co-exclusive right to make or have made Compound extends only to Compound intended for Product to be marketed and sold in MPC Territory. 
  
 3.2 Option to Co-promote. MPC shall have the option to participate in
the promotion of the Product in the MN Territory, on terms to be agreed to by MN. The Parties will negotiate in good faith to enter into a co-promotion agreement within six (6) months of an NDA filing in the United States and an MAA in the Major
European Countries. In case co-promotion is prevented by laws or other regulations in a particular country in the MN Territory, the Parties agree to initiate discussions on how to provide MPC with similar rights in a legally acceptable fashion.

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 10 

 3.3 Sublicense Rights. MN may grant sublicenses within the scope of the license granted to MN
under this Agreement to any Third Party, provided, however, that MN shall obtain prior MPC’s written consent, which shall not be unreasonably withheld or delayed. In the event of any sublicense to a Third Party in each country of the MN
Territory, the provisions of Section 4.5 shall be applicable in such country. 
  
 3.4 Claimed Compound. 
  
 3.4.1 Discussion Right to Claimed Compound. During the period of seven (7) years from the Effective Date, if MPC desires to license to a Third Party a Claimed Compound in the MN Territory, MPC shall discuss
with MN the terms and conditions of license relating to such Claimed Compound prior to discussing or offering to a Third Party. 
  
 3.4.2 Back Up Compound. If the development of the Compound and the Product is terminated by MN, its Affiliate, and its sublicensee
in all countries of the MN Territory because (i) of a serious safety or efficacy problem or (ii) the pharmaceutical properties of the Compound or Product are determined to present a serious problem, and MN desires to develop a Claimed Compound which
is at the stage of clinical trials in human, MN may substitute within six (6) months of its termination of the development of Compound its right, title and interest in and to such Claimed Compound for that of the Compound under this Agreement,
provided, however, that MN shall obtain prior MPC’s written consent, which shall not be unreasonably withheld. 
  
 3.5 Combination Product. If MN or its Affiliate desires to develop and/or commercialize combination products in the MN Territory, MN and MPC shall
discuss in good faith the terms and conditions relating to such development or commercialization of such combination products. For the purpose of this Section 3.5, “combination product” shall mean any product in final form, packaged and
labeled for commercial sale by prescription, or by any other method (or, where the context so indicates, the product being tested in clinical trials), which contains Compound as one of the therapeutically active ingredients and another
therapeutically active ingredient(s) in any dosage form or package configuration. 
  
 3.6 Disclosure of MPC’s Information. Within thirty (30) Business Days after the Effective Date, MPC shall disclose to MN in writing all of the then-available MPC Intellectual Property not previously
disclosed to MN on an as-is basis. During the term of this Agreement, and in addition to the other communications required under this Agreement, MPC shall also promptly disclose to MN in writing on an ongoing basis MPC Intellectual Property and
other information developed in connection with MPC’s activities relating to the Compound and/or the Product, if any. Upon MN’s request, MPC will assist MN in the transition of such manufacturing and supply to MN or its designee, including
providing technology and other transfer services at MPC’s standard FTE rate. 
  
 3.7 Disclosure of MN’s Information. MN shall disclose to MPC for use any and all MN Know-How, including without limitation, IND, NDA, study protocol, information relating 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 11 

 
to marketing the Product and materials for marketing Product (e.g. a brochure or a pamphlet of the Product) from time to time or through the Progress
Report. 
  
 3.8 License Grant to MPC. MN hereby
grants to MPC a non-exclusive royalty-free license including the right to grant sublicenses to MPC Licensees to use the MN Intellectual Property solely to develop, make, have made, use, offer for sale, market, sell, import, and distribute Compound
and Product in the MPC Territory. 
  
 ARTICLE 4 

PAYMENTS AND ROYALTIES 
  
 4.1 Up Front License Fee. In consideration of the rights granted by MPC hereunder, MN shall pay to MPC [**] within ten (10) days after the
Effective Date. 
  
 4.2 Milestone Payments. Subject to the
terms and conditions contained in this Agreement, in further consideration of the rights granted by MPC hereunder, MN shall pay MPC the following milestone payments, contingent upon occurrence of the specified event, with each milestone payment to
be made no more than once with respect to the achievement of such milestone and no amounts shall be due hereunder for any subsequent or repeated achievement of such milestones, regardless of the number of Products for which such milestone may be
achieved (but payable on the first achievement of such milestone): 
  

	 	(a)	An amount equal to the difference between (i) [**] and (ii) the amount, not to exceed [**], incurred by MN for formulation work relating to Compound and/or Product,
upon initiation (dosing of the first patient) of the first Phase 3 Clinical Trial in the MN Territory; 

  

	 	(b)	[**] upon the FDA’s first acceptance for filing of an NDA; 

  

	 	(c)	[**] upon receipt in writing of the first Regulatory Approval in the United States by MN, its Affiliates or its sublicensees; 

  

	 	(d)	[**] upon the EMEA’s first acceptance for filing of an NDA; 

  

	 	(e)	[**] upon receipt in writing of the first Regulatory Approval from the EMEA by MN, its Affiliates or its sublicensees together with Regulatory Approval in at least two (2) of
the Major European Countries; 

  

	 	(f)	[**] upon the achievement of cumulative Net Sales in all MN Territory of [**]; and 

  

	 	(g)	[**] upon the achievement of cumulative Net Sales in all MN Territory of [**]. 

  
 MN shall notify MPC in writing within thirty (30) days after the achievement of the milestones specified in Sections 4.2 (a) through (e) and
each such notice shall be accompanied by the 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 12 

 
appropriate milestone payment. MN shall notify MPC in writing within ninety (90) days after the achievement of the milestones specified in Sections 4.2 (f)
and (g) and any such milestone payment required to be made by MN under such Section 4.2 (f) or (g) shall be paid together with the royalty payment for such Calendar Quarter. 
  
 4.3 Royalties Payable by MN. Subject to the terms and conditions contained in this Agreement, in further
consideration of the license granted by MPC to MN herein, MN shall pay to MPC royalties in the applicable percentages set forth below for Net Sales in each Royalty Year by MN and its Affiliates in the MN Territory: 
  

			
	 Annual (on a Royalty Year basis) Net Sales in all countries in the MN Territory
	 	Royalty Rate
	 On the portion that is less than [**]
	 	[**]
	 On the portion that is greater than or equal to [**] and less than [**]
	 	[**]
	 On the portion that is greater than or equal to [**]
	 	[**]

  
 Royalties on Net Sales
at the rates set forth in this Section 4.3 shall accrue on a country-by-country basis as of the date of First Commercial Sale in an applicable country and shall continue and accrue on Net Sales in such applicable country until the expiration of the
Royalty Term, provided that: 
  
 (a) in an applicable country
where a Valid Patent Claim exists after the expiration of the Royalty Term, the Parties agree to negotiate in good faith the amount of continued royalty payments, if any, in such country, which continued royalty payments, if any, shall in no event
extend beyond the expiration of such Valid Patent Claim; and 
  
 (b) in an applicable country where Generic Competition exists during the Royalty Term, and for as long as such Generic Competition exists in such applicable country, Net Sales from such applicable country shall be reduced by [**]
before including same into the Net Sales in all countries in the MN Territory for the purpose of calculating the applicable royalty rates from the table set forth in this Section 4.3. 
  
 4.4 Compulsory Licenses. If a compulsory license is granted to a Third Party with respect to Product in any country
in the MN Territory with a royalty rate lower than the royalty rate provided in Section 4.3, then the royalty rate to be paid to MPC on Net Sales in that country shall be adjusted in a manner that equates the entry of such compulsory Third Party
licensee with the existence of Generic Competition as set forth in Section 4.3(b). 
  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 13 

 4.5 One Royalty. No royalty shall be payable under this Article 4 with respect to sales of
Products among MN and its Affiliates for resale, nor shall a royalty be payable under this Article 4 with respect to Products distributed for use in research and/or development, in clinical trials, as donations to non-profit institutions or
government agencies or as promotional free samples. 
  
 4.6
Sublicense Payments. In the event MN enters into a sublicense with a Third Party or Third Parties under Section 3.2 of this Agreement granting a sublicense of any rights licensed to MN by MPC under Section 3.1 of this Agreement in any country
in the MN Territory, MN’s obligation to pay MPC milestone payments under Section 4.2 and royalties under Section 4.3 above shall terminate with respect to any milestones or royalties applicable to such country or countries, and, in lieu
thereof, MN shall pay MPC the following applicable percentages of Net Sublicense Consideration applicable to the country or countries subject to the sublicense for so long as MN receives such Net Sublicense Consideration: 
  
 (i) [**] of Net Sublicense Consideration, if a sublicense is entered
into before [**]; or 
  
 (ii) [**] of Net
Sublicense Consideration, if a sublicense is entered into after [**]. 
  
 ARTICLE 5 
 ROYALTY REPORTS AND ACCOUNTING 
  
 5.1 Reports. During the Royalty Term, MN shall furnish to MPC a written report for the Calendar Quarter showing on a
country by country basis, (a) the gross sales of all Products sold by MN and its Affiliates in the MN Territory during such Calendar Quarter and the calculation of Net Sales from such gross sales; (b) the royalties, payable in United States dollars,
which shall have accrued hereunder based upon Net Sales; (c) the withholding taxes, if any, required by law to be deducted in respect of such royalties; (d) the date of the First Commercial Sale of each Product in each country in the MN Territory;
(e) in the case of a sublicense to a Third Party, Net Sublicense Consideration received by MN; and (f) the exchange rates used in determining the amount of United States dollars, as more specifically provided in Section 6.2 below. Reports shall be
due forty-five (45) days following the close of each Calendar Quarter. MN shall keep complete and accurate records in sufficient detail to properly reflect all gross sales and Net Sales and to enable the royalties payable hereunder to be determined.

  
 5.2 Audits. 
  
 5.2.1 Audit Rights. Upon the written request of MPC
and not more than once in each Calendar Year, MN shall permit MPC’s accounting personnel and/or an independent certified public accounting firm of nationally recognized standing, selected by MPC and reasonably acceptable to MN, at MPC’s
expense, to have access during normal business hours on at least ten (10) days’ prior written notice, to such of the records of MN and its Affiliates as may 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 14 

 
be reasonably necessary to verify the accuracy of the royalty reports hereunder for any Royalty Year ending not more than thirty-six (36) months prior to the
date of such request. The accounting representatives shall disclose to MPC only whether the records are correct or not and the specific details concerning any discrepancies. 
  
 5.2.2 Audit Results. If MPC or such accounting firm concludes that additional royalties were owed
during such period, MN shall remit to MPC within thirty (30) days of the date MPC delivers to MN such accounting firm’s or MPC’s written report so concluding: (i) the amount of such additional royalties and (ii) interest on the amount of
such additional royalties which shall be calculated pursuant to Section 6.4; provided, however, that, in the event that MN shall not be in agreement with the conclusion of such report (a) MN shall not be required to pay such additional royalties and
(b) such matter shall be resolved pursuant to the provisions of Section 11.6 herein. In the event such accounting firm concludes that amounts were overpaid by MN during such period, MN shall have a credit against future royalties payable to MPC in
the amount of such overpayment; provided, however, that in the event that MPC shall not be in agreement with the conclusion of such report (a) MN shall not have such a credit and (b) such matter shall be resolved pursuant to the provisions of
Section 11.6 herein. The fees charged by such accounting firm shall be paid by MPC; provided, however, that if an error in favor of MPC of more than seven and one-half percent (7.5%) of the royalties due hereunder for the period being reviewed is
discovered, then MN shall pay the reasonable fees and expenses charged by such accounting firm. Upon the expiration of thirty-six (36) months following the end of any Royalty Year, the calculation of royalties payable with respect to such Royalty
Year shall be binding and conclusive upon MPC and MN shall be released from any liability or accountability with respect to royalties for such Royalty Year. 
  
 5.2.3 Confidential Financial Information. MPC shall treat all financial information subject to review under this Article 5 or under
any sublicense agreement as confidential, and shall cause its accounting firm to retain all such financial information in confidence. 
  
 ARTICLE 6 
 PAYMENTS 
  
 6.1 Payment Terms. Royalties shown to have accrued by each royalty
report provided for under Article 5 of this Agreement shall be due and payable on the date such royalty report is due. In order for MPC to receive compensation on a quarterly basis, MN shall pay to MPC, on a quarterly basis, royalties based on the
cumulative Net Sales for the applicable Royalty Year through the end of such Calendar Quarter, less royalties previously paid to MPC on account of Net Sales for the previous Calendar Quarters in such Royalty Year. 
  
 6.2 Payment Method. All payments by MN to MPC under this Agreement
shall be paid in United States dollars. If any currency conversion shall be required in connection with the payment of any royalties hereunder, such conversion shall be made by using the average of the 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 15 

 
exchange rates for the purchase and sale of United States dollars reported by the Wall Street Journal on the last Business Day of the Calendar Quarter to
which such royalty payments relate. 
  
 6.3 Exchange
Control. If at any time legal restrictions prevent the prompt remittance of part or all royalties with respect to any country in the MN Territory where the Product is sold, MN shall have the right, at its option, to make such payments by
depositing the amount thereof in local currency to MPC’s account in a bank or other depository designated by MPC in such country. If the royalty rate specified in this Agreement should exceed the permissible rate established in any country in
the MN Territory, the royalty rate in such country shall be adjusted to the highest legally permissible or government-approved rate. 
  
 6.4 Overdue Payments. In the event the initial payment, any milestone payment, any royalty payment or payment relating to Net Sublicense
Consideration is not made when due, such outstanding payment shall accrue interest (from the date such payment is due through and including the date upon which full payment is made) at the rate equal to one percent (1%) plus the Prime Rate.
“Prime Rate” for purposes of this Section 6.4 shall mean the prime rate of Citibank, N.A. in New York, New York as published in the Wall Street Journal computed on a daily basis and shall change when and as the Prime Rate changes.

  
 6.5 Withholding Taxes. MN shall be entitled to deduct
from any payment due MPC under this Agreement the amount of any withholding taxes payable by MN or its Affiliates, or any taxes required to be withheld by MN or its Affiliates, to the extent MN or its Affiliates pay to the appropriate governmental
authority on behalf of MPC such taxes, levies or charges. MN shall use reasonable efforts to minimize any such taxes, levies or charges required to be withheld on behalf of MPC by MN or its Affiliates. MN promptly shall deliver to MPC proof of
payment of all such taxes, levies and other charges, together with copies of all communications from or with such governmental authority with respect thereto. MPC shall provide MN with all forms or documentation required by any applicable taxation
laws, treaties or agreements to such withholding or as necessary to claim a benefit thereunder (including, but not limited to, Form W-8BEN and any successor form). 
  
 ARTICLE 7 
 CONFIDENTIALITY AND PUBLICITY 
  
 7.1 Nondisclosure
Obligations. Except as otherwise provided in this Article 7, during the term of this Agreement and for a period of five (5) years thereafter, both Parties shall maintain in confidence and use only for purposes of this Agreement information and
data resulting from or related to the development of the Compound or Products and other information and data supplied by the other Party under this Agreement marked “Confidential.” For purposes of this Article 7, information and data
described in this Section shall be deemed “Proprietary Information.” 
  
 7.2 Permitted Disclosures. To the extent it is reasonably necessary or appropriate to fulfill its obligations or exercise its rights under this Agreement, (a) a Party may disclose Proprietary Information which
is otherwise obligated under this Article 7 not to disclose to its 
  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 16 

 
Affiliates, to MPC Licensees, if the Party is MPC, to its sublicensees, if the Party is MN, and to its consultants, outside contractors and clinical
investigators, on a need-to-know basis on condition that such Persons agree to keep the Proprietary Information confidential for the same time periods and to the same extent as such Party is required to keep the Proprietary Information confidential;
and (b) a Party (including MN’s sublicensees or MPC Licensees) may disclose such Proprietary Information to government or other regulatory authorities to the extent that such disclosure is required by applicable law (including without
limitation all applicable securities laws), regulation, agency or court order, or is reasonably necessary to obtain patents or authorizations to conduct clinical trials with, and to commercially market the Product, provided that the disclosing Party
shall provide written notice to the other Party and sufficient opportunity to object to such disclosure or to request confidential treatment thereof. The obligation not to disclose or use Proprietary Information received from the other Party shall
not apply to any part of such Proprietary Information that (i) is or becomes patented, published or otherwise part of the public domain other than by acts of the Party obligated not to disclose such Proprietary Information in contravention of this
Agreement; (ii) is disclosed to the receiving Party by a Third Party, provided such Proprietary Information was not obtained by such Third Party directly or indirectly from the other Party on a confidential basis; (iii) prior to disclosure under
this Agreement, was already in the possession of the receiving Party, provided such Proprietary Information was not obtained directly or indirectly from the other Party; (iv) is subsequently and independently developed by the receiving Party without
the knowledge of the Proprietary Information or (v) is disclosed in a press release agreed to by both Parties, which agreement shall not be unreasonably withheld. 
  
 ARTICLE 8 
 INTELLECTUAL PROPERTY AND INFRINGEMENT 
  
 8.1
Ownership of Improvements. The entire right and title in all Improvements, and any Patent Assets based thereon, made or conceived during the term of this Agreement by employees or others acting on behalf of MN or its Affiliates shall be owned
solely by MN. The entire right and title in all Improvements, and any Patent Assets based thereon, made or conceived during the term of this Agreement by employees or others acting on behalf of MPC or its Affiliates shall be owned solely by MPC,
subject to the licenses granted to MN under this Agreement 
  
 8.2
Ownership of Trademarks. MN shall select, own and maintain Trademarks for Product in the MN Territory. The entire right and title in all Trademarks used by MN, its Affiliates and, if applicable, its sublicensees, in the MN Territory shall be
owned solely by MN. In case MPC desires to use the Trademark for the Product in the MPC Territory, MN shall grant MPC a royalty-free exclusive license, with the right to grant sublicenses, to use the Trademark for the Product during and after
expiration or termination of this Agreement in the MPC Territory. 
  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 17 

 8.3 Patent Prosecution and Maintenance. MPC shall have the initial right to control the filing,
prosecution and maintenance of the MPC Patent Assets in the MPC Territory and the MN Territory, and to select all patent counsel or other professionals to advise, represent or act for it in all matters relating to the MPC Patent Assets. MPC shall be
responsible for the payment of all such patent prosecution and maintenance costs. MPC shall solicit MN’s review of the nature and text of any such patent applications in the MN Territory and important prosecution matters related thereto in
reasonably sufficient time prior to filing thereof, and MPC shall take into account MN’s reasonable comments related thereto. MPC shall inform MN of any significant developments in the prosecution of pending patent applications included in the
MPC Patent Assets, including the issuance of any final office actions, allowance of claims, or upcoming grant of any domestic or foreign patent based thereon. If MPC decides not to file, prosecute or maintain a Patent Asset included in the MPC
Patent Assets in any country in the MN Territory, it shall provide MN with written advance notice sufficient to avoid any loss or forfeiture (but in any event at least sixty (60) days notice), and MN shall have the right but not the obligation, at
its sole expense, to file, prosecute or maintain such patent application in MPC’s name and, if MN elects to do so, MPC shall assign to MN all of MPC’s right, title and interest in and to such MPC Patent Assets in the MN Territory and such
Patent Asset shall no longer be deemed an MPC Patent Asset in the MN Territory. MN shall have the right to control the filing, prosecution, and maintenance of the MN Patent Assets in the MN Territory and the MPC Territory, and to select all patent
counsel or other professionals to advise, represent or act for it in all matters relating to the MN Patent Assets. MN shall be responsible for the payment of all such patent prosecution and maintenance costs. If MN elects not to file, prosecute or
maintain a Patent Asset included in the MN Patent Assets in any country in the MPC Territory, it shall provide MPC with written advance notice sufficient to avoid any loss or forfeiture (but in any event at least sixty (60) days notice), and MPC
shall have the right but not the obligation, at its sole expense, to file, prosecute or maintain such patent application in MPC’s name and, if MPC elects to do so, MN shall assign to MPC all of MN’s right, title and interest in and to such
MN Patent Assets in the MPC Territory and such Patent Asset shall no longer be deemed an MN Patent Asset in the MPC Territory. 
  
 8.4 Cooperation. Each Party shall make available as far as possible to the other Party or to the other Party’s authorized attorneys, agents,
representatives, employees or consultants any documents necessary or appropriate to enable the other Party to file, prosecute and maintain patent applications and resulting patents, as set forth in Section 8.3 above, for a period of time sufficient
for the other Party to obtain the assistance it needs from the first Party. Where appropriate, each Party shall sign or cause to have signed all documents relating to said patent applications or patents at no charge to the other Party. 

 
 8.5 Enforcement of Patent Assets. In the event either Party learns
of significant and continuing infringement of the MPC Patent Assets, it shall promptly provide written notice to the other Party of the fact and supply such other Party with all evidence it possesses pertaining to and establishing said
infringement(s). MN shall have the first right to enforce the MPC Patent Assets against infringers in the MN Territory, and shall consult with MPC both prior to and during said enforcement. 
  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 18 

 8.6 Procedure for Enforcement of Patent Assets. MN shall have six (6) months from the date of
receipt of notice of request by MPC to abate the infringement, or to file suit against at least one of the infringers, at the sole expense of MN, following consultation with MPC. If MN does not, within six (6) months of receipt of such notice, abate
the infringement or file suit to enforce the MPC Patent Assets against at least one infringer in a country in the MN Territory, MPC shall have the right to take whatever action it deems appropriate in its own name to enforce the MPC Patent Assets in
the MN Territory; provided, however, that, within thirty (30) days after receipt of notice of MPC’s intent to file such suit, MN shall have the right to jointly prosecute such suit. 
  
 8.7 Settlements. The Party controlling the action may not settle the action or otherwise consent to an adverse
judgment in such action that diminishes the rights or interests of the non-controlling Party without the express written consent of the non-controlling Party. Notwithstanding the foregoing, MPC and MN shall cooperate with each other in the planning
and execution of any action to enforce the MPC Patent Assets. Any recovery obtained by MN or MPC shall be shared as follows: 
  
 (i) the Party that initiated and prosecuted, or maintained the defense of, the action shall recoup all of its costs and expenses (including reasonable
attorneys’ fees) incurred in connection with the action, whether the recovery is by settlement or otherwise; 
  
 (ii) the other Party then shall, to the extent possible, recover its costs and expenses (including reasonable attorneys’ fees) incurred in connection
with the action; 
  
 (iii) if MPC initiated and prosecuted, or
maintained the defense of, the action, the amount of any recovery remaining then shall be retained by MPC; and 
  
 (iv) if MN initiated and prosecuted, or maintained the defense of, the action, the amount of any recovery remaining shall be retained by MN, except that
MPC shall receive a portion equivalent to the royalties it would have received in accordance with the terms of this Agreement if the amount of any remaining recovery had been Net Sales. 
  
 8.8 Notification of Patent Term Restoration. The Parties shall cooperate with each other in obtaining patent term
restoration or supplemental protection certificates or their equivalents in any country where applicable to the MPC Patent Assets in the MN Territory and the MPC Territory. Each Party shall notify the other if it becomes aware of (a) the issuance of
a patent included within the MPC Patent Assets, giving the date of issue and patent number for each such patent, and (b) each notice pertaining to any patent included within the MPC Patent Assets pursuant to the United States Drug Price Competition
and Patent Term Restoration Act of 1984 (hereinafter called the “1984 Act”), including notices pursuant to §§ 101 and 103 of the 1984 Act from persons who have filed an abbreviated NDA (“ANDA”). Such notices shall be
given promptly, but in any event within five (5) days of each such patent’s date of issue or receipt of each such notice pursuant to the 1984 Act, whichever is applicable. MN shall notify MPC of each filing for patent term restoration under the
1984 Act, and all awards of patent term restoration (extensions) with respect to the MPC Patent Assets. Likewise, MPC or MN, as the 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 19 

 
case may be, shall inform the other Party of patent extensions and periods of data exclusivity in the rest of the world regarding any Product. 
  
 8.9 Infringement Actions by Third Parties. If MN or any of its
Affiliates shall be sued by a Third Party for infringement of a patent held by such Third Party because of the manufacture, importation, use, offer for sale or sale of the Compound or Products under MPC Intellectual Property, MN shall promptly
notify MPC in writing of the institution of such suit. MN shall have the first right, in its sole discretion, to control the defense of such suit at its own expense, in which event MPC shall have the right to be represented by advisory counsel of
its own selection, at its own expense, and shall cooperate fully in the defense of such suit and furnish to MN all evidence and assistance in MPC’s control. If MN does not elect within thirty (30) days after such notice from MN to MPC to so
control the defense of such suit, MPC may undertake such control at its own expense, and MN shall then have the right to be represented by advisory counsel of its own selection and at its own expense, and MN shall cooperate fully in the defense of
such suit and furnish to MPC all evidence and assistance in MN’s control. The Party controlling the suit may not settle the suit or otherwise consent to an adverse judgment in such suit that diminishes the rights or interests of the
non-controlling Party without the express written consent of the non-controlling Party. The royalty or other payments required to be paid by MN or its Affiliates to any Third Party as the result of a judgment or settlement under this Section 8.9
shall be creditable against the royalty payments pursuant to Section 4.3 due MPC with respect to the sale of such Product in such country, provided, however, that in no event shall the royalties payable to MPC pursuant to Section 4.3 be reduced to
less than fifty percent (50%) of the amount due under this Agreement. 
  
 ARTICLE 9 
 TERM AND TERMINATION 
  
 9.1 Expiration. Unless terminated earlier pursuant to Sections 9.2 or 9.3 below, this Agreement shall expire on a country-by-country basis on the
expiration of the Royalty Term in such country, subject, however, to continued royalty payments, if any, under Section 4.3(a). Notwithstanding the above, in case that MN enters into a sublicense with a Third Party or Third Parties, the obligation of
the payment by MN to MPC relating to Net Sublicense Consideration pursuant to Section 4.7 shall survive until the expiration of the period in which MN receives Net Sublicense Consideration from such sublicensee. Expiration of this Agreement in a
particular country under this provision shall not preclude MN from continuing to develop, make, have made, use, sell, offer for sale, and import Product in such country without further remuneration to MPC, subject, however, to continued royalty
payments, if any, under Section 4.3(a). 
  
 9.2 Termination by
MN. MN shall have the right, in its sole discretion, to terminate this Agreement (a) by providing not less than thirty (30) days prior written notice of such termination to MPC, with respect to the entire Agreement, or with respect to any
country in the MN Territory in the event that a Third Party claims that Compound or Product infringes such Third Party’s intellectual property in any country in the MN Territory, or (b) by providing not less than ninety (90) days written notice
to MPC if in MN’s reasonable opinion the safety, 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 20 

 
patient tolerability, efficacy, or the profile or the commercial viability of the Product does not justify continued development by MN, its Affiliate and/or
its sublicensee with respect to the entire Agreement, or with respect to any country in the MN Territory. Subject to the provisions of Section 9.4 below, the rights and obligations of MPC and of MN with respect to this Agreement in its entirety or
with respect to the terminated country in the MN Territory, as applicable, shall terminate in the event of a termination pursuant to this Section 9.2, provided, however, that in the event of a partial termination by MN under this
Section 9.2, this Agreement shall continue in full force and effect with respect to the countries in the MN Territory unaffected by such partial termination, and such country shall be excluded from the countries of the MN Territory. 
  
 9.3 Termination for Cause. (a) Either Party may terminate this
Agreement upon or after the breach of any material provision of this Agreement by the other Party, if the breaching Party has not cured such breach within ninety (90) days after notice thereof from the non-breaching Party. This Agreement shall
terminate, at the option of the non-breaching Party, at the expiration of such ninety (90) day cure period; provided, however, that if the breach is not capable of being cured within ninety (90) days of such written notice, this Agreement may not be
terminated so long as the breaching Party commences and is taking commercially reasonable actions to cure such breach as promptly as practicable. 
  
 (b) Either Party may terminate this Agreement upon giving notice to the other Party, which termination notice shall have immediate effect, in the case of
any adjudication of bankruptcy or insolvency, appointment of a receiver by a court of competent jurisdiction, assignment for the benefit of creditors, or institution of liquidation proceedings by or against the other Party provided, however, in the
case of any involuntary bankruptcy, reorganization, liquidation, receivership or assignment proceeding such right to terminate shall only become effective if the Party consents to the involuntary proceeding or such proceeding is not dismissed within
ninety (90) days after the filing thereof. 
  
 9.4 Effect of
Expiration and Termination. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing on or prior to such expiration or termination. MN and its Affiliates and sublicensees shall have the right to sell
or otherwise dispose of the stock of any Product subject to this Agreement then on hand or in process of manufacture, subject to Articles 4, 5 and 6. In addition to any other provisions of this Agreement which by their terms continue after the
expiration of this Agreement, the provisions of Article 7 shall survive the expiration or termination of this Agreement and shall continue in effect during the term set forth in Section 7.1. In addition, any other provision required to interpret and
enforce the Parties’ rights and obligations under this Agreement shall also survive, but only to the extent required for the full observation and performance of this Agreement. Except as expressly set forth herein, the rights to terminate as
set forth herein shall be in addition to all other rights and remedies available under this Agreement, at law, or in equity, or otherwise. 
  
 9.4.1 Effect of Termination Without MPC’s Cause. In the event this Agreement shall be terminated by MPC pursuant to Section
9.3 or terminated by MN pursuant to Section 9.2, 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 21 

 
MN and its Affiliate shall promptly return to MPC or destroy all MPC Intellectual Property and all copies thereof, and may thereafter not use any such MPC
Intellectual Property. Further, MN and its Affiliate shall furnish MPC with all MN Intellectual Property not already provided to MPC with a right to use and have used. Further, MN and/or its Affiliate shall transfer to MPC or its nominee any IND,
NDA or other documents filed with any Regulatory Authorities in MN Territory and Regulatory Approvals obtained in the MN Territory free of charge. MN and its Affiliate shall, at the request of MPC, cooperate with MPC or its nominee for the smooth
transfer of them. In consideration of the foregoing, in the event such termination occurs after commencement of a pivotal clinical trial of Product, MN shall be entitled to a royalty equal to [**] of net sales of Product in the MN Territory
for a period of seven (7) years from the date of such termination of this Agreement, except if such termination resulted from a material breach by MN.  
  

9.4.2 Effect of Termination for MPC’s Cause. In the event this Agreement shall be terminated by MN pursuant to Sections 9.3
, MN shall have an irrevocable, perpetual and exclusive license under MPC Intellectual Property to develop, make, have made, use, offer for sale, market, sell, import, and distribute Compound and Product in the MN Territory; provided, however, that,
the applicable royalty rates set forth in Section 4.3 or sharing rate set forth in Section 4.6 shall be reduced by fifty percent (50%). Further, MPC’s license granted by MN pursuant to Section 3.5 shall be amended from royalty-free license to
royalty-bearing license. MPC shall pay royalties to MN equal to [**] of all net sales of the Products in the MPC Territory for a period of five (5) years from the date of such termination of this Agreement. 
  
 ARTICLE 10 
 REPRESENTATIONS AND WARRANTIES 
  
 The Parties hereby represent and warrant as follows: 
  
 10.1 Corporate Existence and Power. Such Party (a) is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated; and (b) has the
corporate power and authority and the legal right to own and operate its property and assets, to lease the property and assets it operates under lease, and to carry on its business as it is now being conducted; 
  
 10.2 Authorization and Enforcement of Obligations. Such Party (a) has
the corporate power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder and (b) has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and
the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms; 

 

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 22 

 10.3 Consents. All necessary consents, approvals and authorizations of all governmental
authorities and other Persons required to be obtained by such Party in connection with this Agreement have been obtained; 
  
 10.4 No Conflict. The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder (a) do not conflict
with or violate any requirement of applicable laws or regulations and (b) do not conflict with, or constitute a default under, any contractual obligation of such Party; and 
  
 10.5 Ownership, Validity and Non-Infringement. As of the Effective Date, MPC represents and warrants to MN that: (a)
the MPC Intellectual Property are owned or Controlled solely and exclusively by MPC free and clear of any liens, charges and encumbrances, and no other person, corporate or other private entity, or governmental or university entity or subdivision
thereof, has any valid claim of ownership with respect to the MPC Intellectual Property, whatsoever; (b) MPC has not previously granted, and will not grant during the term of this Agreement, any right, license or interest in and to the MPC
Intellectual Property, or any portion thereof, inconsistent with the license granted to MN herein; (c) MPC is not aware of the existence of any references or conduct that would bring into question the validity or enforceability of the MPC
Intellectual Property in the Field except for ophthalmology; (d) there are no threatened or pending actions, suits, investigations, claims or proceedings in any way relating to the MPC Intellectual Property; (e) the MPC Intellectual Property and the
contemplated development, importation or exportation, manufacture, use, offer for sale and sale of any Compound or Product in the Field except for ophthalmology, do not infringe any patent rights owned or possessed by any Third Party; (f) MPC has
disclosed to MN all information known by it that is reasonably believed by MPC to be related to the MPC Intellectual Property (including all information received by MPC concerning the institution or possible institution of any interference,
opposition, re-examination, reissue, revocation, nullification, or any official proceeding involving a MPC Patent Asset, and will continue such disclosure with respect to new events during the term of the Agreement) and the activities contemplated
under this Agreement; and (g) Schedule 1.33 contains a complete and accurate list of all patents and patent applications relating to Compound or Product owned or Controlled by MPC in the Field. 
  
 10.6 Supply of API. MPC represents and warrants that the manufacture,
testing and storage of API supplied to MN under this Agreement shall be in compliance with cGMP and all other applicable laws and regulations. For the purpose of Section 303(c) of the Act, all API supplied will not, on the date of shipment, be
adulterated or misbranded within the meaning of the Act and the regulations issued thereunder or within the meaning of any other applicable law, rules or regulations, the provisions of which are in effect at the time of such shipment, and will not
be an article which may not, under the provisions of Section 404 or 505 of the Act, be introduced into interstate commerce. MPC further represents and warrants that API supplied to MN under this Agreement shall be free of any lien, security,
interest or other encumbrance on title and shall be free of defects in material and workmanship. 
  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 23 

 10.7 Funding. MN represents and warrants that it intends to allocate a commercially reasonable
level of its available corporate funds to perform its development obligations under this Agreement. 
  
 10.8 Effect of Representations and Warranties. It is understood that if the representations and warranties made by a Party under this Article 10
are not true and accurate, and the other Party incurs damages, liabilities, costs or other expenses as a result, the Party making such representations and warranties shall indemnify and hold the other Party harmless from and against any such
damages, liabilities, costs or other expenses incurred as a result. Notwithstanding the foregoing, if the representations and warranties made by MPC under Section 10.5(e) are not true and accurate, and the other Party incurs damages, liabilities,
costs or other expenses as a result, Section 8.9 shall operate to indemnify MN and MPC shall have no further obligation to compensate MN for such damages, liabilities, costs or other expenses incurred as a result. 
  
 10.9 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY
MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR VALIDITY OF ANY PATENT ASSETS ISSUED OR
PENDING. 
  
 ARTICLE 11 
 INDEMNIFICATION 
  
 11.1 MN’s Obligation. MN shall defend, indemnify, and hold harmless MPC, its Affiliates and their respective directors, officers,
shareholders, employees and agents (“MPC Indemnitees”), from and against any and all liabilities, damages, losses, penalties, fines, costs, interest, and expenses, including, but not limited to reasonable attorney’s fees
(“Damages”) arising from or occurring as a result of a Third Party’s claim, action, suit, judgment or settlement against an MPC Indemnitee that is due to or based upon: 
  
 (a) any breach of a representation, warranty, covenant or agreement of MN under this Agreement, 

 
 (b) any negligent or more culpable act of MN, its
Affiliates or its sublicensees under this Agreement, or 
  
 (c) development, manufacture, use, sale or labeling of Compound, API or Product by MN, its Affiliates or its sublicensees. 
  
 However, MN shall not indemnify or hold harmless MPC Indemnitees from Damages to the extent that such Damages are finally determined to have resulted from the acts or
omissions of an 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 24 

 
MPC Indemnitee. MN’s obligations under this Section shall survive the expiration or termination of this Agreement for any reason. 
  
 11.2 MPC’s Obligation. MPC shall defend, indemnify, and hold
harmless MN, its Affiliates and their respective directors, officers, shareholders, employees and agents (“MN Indemnitees”), from and against any and all Damages arising from or occurring as a result of a Third Party’s claim, action,
suit, judgment or settlement against an MN Indemnitee that is due to or based upon: 
  
 (a) any breach of a representation, warranty, covenant or agreement of MPC under this Agreement, 
  
 (b) any negligent or more culpable act of MPC, its
Affiliates or its sublicensees under this Agreement, or 
  
 (c) development, manufacture, use, sale, promotion or labeling of Compound, API or Product by MPC, its Affiliates or its sublicensees. 
  
 However, MPC shall not indemnify or hold harmless MN Indemnitees from Damages to the extent that such Damages are finally determined to have
resulted from the acts or omissions of an MN Indemnitee. MPC’s obligations under this Section shall survive the expiration or termination of this Agreement for any reason. 
  
 11.3 Insurance. MN shall maintain and keep in force for the term of this Agreement comprehensive general liability
insurance including Products/Completed Operations, Contractual and Broad Form Property Damage covering its indemnification obligations hereunder combined single limit for Bodily Injury and Property Damage. It is understood that such insurance shall
not be construed to limit MN’s liability with respect to such indemnification obligations. Such insurance shall be placed with a first class insurance carrier with at least BBB rating by Standard & Poor. Prior to initiation of each clinical
trial, MN shall furnish a certificate of insurance to MPC (or provide MPC with a written affirmation of the adequacy of an existing certificate) evidencing the foregoing endorsements, coverage and limits, and providing that such insurance shall not
expire or be canceled or modified without reasonable prior notice to MPC. 
  
 ARTICLE 12 
 MISCELLANEOUS 
  
 12.1 Force Majeure. Neither Party shall be held liable or responsible to the other Party nor be deemed to have
defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement to the extent, and for so long as, such failure or delay is caused by or results from causes beyond the reasonable control of the
affected Party including but not limited to fire, floods, embargoes, power shortage or failure, war, acts of war (whether war be declared or not), terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts
of God or acts, omissions or delays in acting by any governmental authority or the other Party. 
  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 25 

 12.2 Assignment. This Agreement may not be assigned or otherwise transferred, nor, except as
expressly provided hereunder, may any right or obligations hereunder be assigned or transferred by either Party without the consent of the other Party; provided, however, that either MPC or MN may, without such consent, assign this Agreement
and its rights and obligations hereunder to an Affiliate or in connection with the transfer or sale of all or substantially all of its business, or in the event of its merger or consolidation or change in control or similar transaction. Any
permitted assignee shall assume all obligations of its assignor under this Agreement. 
  
 12.3 Severability. Each Party hereby acknowledges that it does not intend to violate any public policy, statutory or common laws, rules, regulations, treaty or decision of any government agency or executive
body thereof of any country or community or association of countries. Should one or more provisions of this Agreement be or become invalid, the Parties shall substitute, by mutual consent, valid provisions for such invalid provisions which valid
provisions in their economic effect are sufficiently similar to the invalid provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such provisions. In case such provisions cannot be agreed upon, the
invalidity of one or several provisions of the Agreement shall not affect the validity of this Agreement as a whole, unless the invalid provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the
Parties would not have entered into this Agreement without such invalid provisions. 
  
 12.4 Notices. Any consent, notice or report required or permitted to be given or made under this Agreement by one of the Parties to the other shall be in writing, delivered personally or by facsimile or email
(and promptly confirmed by personal delivery, U.S. first class mail or courier), U.S. first class mail or courier, postage prepaid (where applicable), addressed to such other Party at its address indicated in the first paragraph of this Agreement,
or to such other address as the addressee shall have last furnished in writing to the addressor and (except as otherwise provided in this Agreement) shall be effective upon receipt by the addressee. 
  
 12.5 Applicable Law. This Agreement shall be governed by and construed
in accordance with the laws of the State of New York without regard to the conflicts of law principles thereof except matters of patent law, which shall be determined in accordance with the national intellectual property laws relevant to the Patent
Asset in question. 
  
 12.6 Dispute Resolution. (a) The
Parties agree to attempt initially to solve all claims, disputes, or controversies arising under, out of, or in connection with this Agreement (a “Dispute”) by conducting good faith negotiations. Any Disputes which cannot be resolved by
good faith negotiation within thirty (30) days, shall be referred, by written notice from either Party to the other, to the Chief Executive Officer of each Party. Such Chief Executive Officers shall negotiate in good faith to achieve a resolution of
the Dispute referred to them within thirty (30) days after such notice is received by the Party to whom the notice was sent. If the Chief Executive Officers are unable to settle the Dispute between themselves within thirty (30) days, they shall so
report to the Parties in writing. The Dispute shall then be referred to arbitration as set forth in the following subsection (b). 
  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 26 

 (b) Upon the Parties receiving the Chief Executive Officers’ report that the Dispute referred to
them pursuant to subsection (a) has not been resolved, a Party shall decide to institute arbitration proceedings, it shall give written notice to that effect to the other Party. The Parties shall refrain from instituting the arbitration proceedings
for a period of sixty (60) days following such notice. During such period, the Parties shall continue to make good faith efforts to amicably resolve the dispute without arbitration. If the Parties have not reached a settlement during that period the
arbitration proceedings shall go forward and be governed by the rules of the American Arbitration Association (“AAA”) then in force. Each such arbitration shall be conducted by a panel of three arbitrators: one arbitrator shall be
appointed by each of MN and MPC and the third arbitrator, who shall be the Chairman of the tribunal, shall be appointed by the two-Party appointed arbitrators. Any such arbitration shall be held in New York, USA and the language of the arbitration
shall be English. 
  
 The tribunal shall issue its award within
forty-five (45) days after the date on which the arbitration proceedings have closed. The arbitrators shall have the authority to grant specific performance. Judgment upon the award so rendered may be entered in any court having jurisdiction or
application may be made to such court for judicial acceptance of any award and an order of enforcement, as the case may be. In no event shall a demand for arbitration be made after the date when institution of a legal or equitable proceeding based
on such claim, dispute or other matter in question would be barred by the applicable statute of limitations. Each Party shall bear its own costs and expenses incurred in connection with any arbitration proceeding and the Parties shall equally share
the cost of the arbitration levied by the AAA. 
  
 12.7 Non
Competition. MN and/or its Affiliate agrees that it shall not, directly or indirectly, develop, have developed, sell or market any 5-HT1A agonist in the Field in the MN Territory (other than Compound). 
  
 12.8 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE
OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES ARISING OUT OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY. 
  
 12.9 Further Assurances. At any time or from time to time on and after the date of this Agreement, each Party shall at the request of the other (i)
deliver to the other such records, data or other documents consistent with the provisions of this Agreement, (ii) execute, and deliver or cause to be delivered, all such consents, documents or further instruments of transfer or license, and (iii)
take or cause to be taken all such actions, as such Party or the other Party may reasonably deem necessary or desirable in order for the other Party to obtain the full benefits of this Agreement and the transactions contemplated herein. 

 
 12.10 Entire Agreement. This Agreement contains the entire
understanding of the Parties with respect to the subject matter hereof. All express or implied agreements and understandings, either oral or written, heretofore made are expressly superseded by this 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 27 

 
Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by both Parties. 
  
 12.11 Headings. The captions to the several Articles and Sections
hereof are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the several Articles and Sections hereof. 
  
 12.12 Independent Contractors. It is expressly agreed that MPC and MN shall be independent contractors and that the relationship between the two
Parties shall not constitute a partnership, joint venture or agency. Neither MPC nor MN shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party,
without the prior written consent of the other Party to do so. 
  
 12.13 Waiver. The waiver by either Party of any right hereunder or the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other
Party whether of a similar nature or otherwise. 
  
 12.14
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 [Remainder of page intentionally left blank.] 
  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 28 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above.

  

			
	MEDICINOVA, INC.
		
	By:	 	 /s/ Takashi Kiyoizumi

	 Name:
	 	 Takashi Kiyoizumi, M.D., Ph.D.

	 Title:
	 	 President and CEO

  

			
	MITSUBISHI PHARMA CORPORATION
		
	By:	 	 /s/ Akihiro Tobe

	 Name:
	 	 Akihiro Tobe, Ph.D.

	 Title:
	 	Managing Executive Officer, Division Manager, Strategic Planning Division

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 29 

  
 SCHEDULE 1.10 
  
 Diagram of [**] 
  
 [**] 
  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 SCHEDULE 1.33 
  
 MPC Patent Assets 
  
 [**] 
  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 SCHEDULE 2.1 
  
 Program 
  
 [**] 
  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION.Master Services Agreement

  
 Exhibit 10.9

  
 **CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM
THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 Master Services Agreement 
  
 This Master Services Agreement (“Agreement”) is made on the 1st day of December 2003, by and between: 
  

	 	1.	Asahi Kasei Pharma Corporation 

 9-1 Kanda Mitoshiro-cho

 Chiyoda-ku, Tokyo 101-8481 
 Japan 
  
 and 
  

	 	2.	MediciNova, Inc. 

 4350 La Jolla Village Drive 

- Suite 950 
 San Diego, CA 92122

 USA 
  
 WHEREAS 
  

	A.	Asahi Kasei Pharma Corporation (hereinafter referred to as Asahi) is a pharmaceutical company focusing on discovery, development and commercialisation of therapeutic agents.

  

	B.	MediciNova, Inc. (hereinafter referred to as MediciNova) is engaged in the business of planning and managing pharmaceutical development programs, in addition to development and
commercialisation of therapeutic agents. 

  

	C.	Asahi may wish to retain the services of MediciNova from time to time to perform Services in connection with the development of pharmaceuticals as more fully set forth in various
project specific addenda to be attached to this Agreement and incorporated herein by reference (Project Addendum). 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Page 1 of 14 

	D.	MediciNova desires to assist Asahi in organizing, monitoring and supervising certain development activities and Asahi desires to retain MediciNova in accordance with the terms and
conditions of this Agreement and attached Project Addendum. 

  

	E.	Asahi and MediciNova entered into a Confidentiality and Non-Disclosure Agreement dated October 10, 2003 (referred to herein as the “Confidentiality Agreement”, the terms
of which remain in full force and effect) . 

  
 NOW, FOR GOOD AND VALUABLE CONSIDERATION (THE SUFFICIENCY OF WHICH IS ACKNOWLEDGED BY BOTH PARTIES), IT IS HEREBY AGREED AS FOLLOWS: 
  

	1.	DEFINITIONS 

  

	1.1.	Unless the context requires otherwise, the following expressions have the following meanings: 

  

	 	1.1.1. 	“Affiliate” means a company or other entity, which directly or indirectly controls, is controlled by or is under common control together with a Party to this Agreement.
For the purposes of this Agreement, the word “control” means the power to vote on or direct the affairs of such company or entity by reason of ownership or control of more than half the voting stock or management or control by agreement.

  

	 	1.1.2. 	“Background IPR” means such Asahi’s intellectual property rights, results, data and materials that Asahi deems necessary or desirable for the conduct of the Services,
including without limitation patents and patent applications relating thereto not generated under a Study but already in existence at the Effective Date and owned by, licensed to or otherwise controlled by Asahi or its Affiliates.

  

	 	1.1.3. 	“Client Information” has the meaning given in Section 5.1. 

  

	 	1.1.4. 	“Compound” means the drug to be investigated and/or developed. 

  

	 	1.1.5. 	“Documentation” means all records in any form (including paper documents, electronic, magnetic and optical records) describing methods and conduct of the Services, factors
affecting the Services and the action taken including (without prejudice to the generality of the foregoing) the Protocols, copies of submissions and approvals from the necessary authorities and the ethics committee, investigators’ curricula
vitae, consent forms, monitor reports, audit certificates, correspondence, reference ranges, raw data, samples, completed case report forms and the reports. 

  

	 	1.1.6. 	“Effective Date” means December 1, 2003. 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Page 2 of 14 

	 	1.1.7. 	“Intellectual Property Rights” means any inventions (whether patentable or not), patents, registered designs, registered trade marks or applications for any of the above,
copyright, design right, unregistered trade marks or business names and technical Know-How and all other proprietary rights and similar rights in any jurisdiction that are conceived, created, developed or reduced to practice as a result of or in
connection with the Services (whether made by MediciNova or its Affiliates alone, together with MediciNova or another third party) except for the MediciNova Property defined in Section 5.1. 

  

	 	1.1.8. 	“Know-How” means all technical, clinical and other information generated as a result of or in connection with the Services including (but not limited to) all Study Data,
knowledge, inventions, formulae, specimens, specifications, procedures, tests, samples, reports, results and techniques arising therefrom. Notwithstanding the foregoing, Know-How does not include MediciNova’s own data obtained as a result of or
in connection with the Services and all other MediciNova information of a privileged and/or proprietary nature not specific to the Services, including, without limitation, MediciNova Property (as defined in Section 5.1) which are and remain the sole
and exclusive property of MediciNova. 

  

	 	1.1.9. 	“Protocol” means the approved protocol for a Study described in a Project Addendum. 

  

	 	1.1.10. 	“Services” means the work described in a Project Addendum. 

  

	 	1.1.11. 	“Study” means a trial performed which utilizes the Services provided hereunder. 

  

	 	1.1.12. 	“Study Data” means the source data and the raw patient data generated directly from a Study on standardized case report forms and related material (including but not
limited to copies of correspondence, hospital discharge summaries, patient notes and laboratory results). For the purposes of this Agreement, physical representations of the data (including without limitation charts, graphs, figures and study
reports containing those physical representations) will also be designated as Study Data. 

  

	 	1.1.13. 	“Suppliers” means any organization or persons subcontracted by MediciNova and authorized by Asahi under Section 3.3 to provide services to aid in the assessment and
implementation of the Services. 

  

	1.2.	References to the singular include the plural and vice versa. 

  

	1.3.	Paragraph headings are for ease of reference only and are not part of this Agreement for the purpose of construction. 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Page 3 of 14 

	2.	APPOINTMENT AND SCOPE - PROJECT ADDENDUM 

  

	2.1.	In the event that the Parties reach agreement with respect to particular Services, one or more Project Addenda will be created. A Project Addendum will be attached to this Agreement
and will collectively, independent from other Project Addenda, constitute together with this Agreement the entire agreement for the specific Services. No Project Addendum will be attached to this Agreement without first being executed by the Parties
hereto. To the extent any terms set forth in a Project Addendum conflict with the terms set forth in the Agreement, the terms of the Project Addendum will control. 

  

	2.2.	For the avoidance of doubt, nothing in this Agreement will prevent or restrict Asahi from appointing any such other persons or entities to conduct the same or similar Services.

  

	3.	THE SERVICES 

  

	3.1.	MediciNova hereby agrees to provide to Asahi the Services at all times during this Agreement in accordance with the terms and conditions set out in each Project Addendum
attached to this Agreement. In performing the Services, MediciNova will comply with this Agreement, the applicable Project Addendum and specified financial agreements, relevant professional standards and all applicable laws, rules, guidelines and
regulations, including, but not limited to, the Federal Food, Drug and Cosmetic Act and/or relevant European Union regulations. 

  

	3.2.	MediciNova will perform the Services under the direction of the MediciNova employee identified as the Project Leader in the applicable Project Addendum or such other person,
acceptable to Asahi, as MediciNova may from time to time designate the Project Leader. 

  

	3.3.	MediciNova may sub-contract any one or more of the Services only with the prior written approval of Asahi. With regard to any such sub-contract, MediciNova will:

  

	 	3.3.1.	 ensure and be responsible for the compliance by any Supplier with the terms and conditions of this Agreement (including without limitation the terms of confidentiality,
Intellectual Property Rights and access to Study Data); 

  

	 	3.3.2.	 include in the sub-contract provisions consistent with this Agreement for the benefit of Asahi. 

  

	3.4.	Each Project Addendum will include a detailed and specific transfer of obligations from Asahi to MediciNova as required by 21 CFR 312.52. 

  

	3.5.	 If Asahi wishes to change the scope of the Services or wishes to obtain additional Services not initially covered by this Agreement and/or not listed in the Project
Addenda, Asahi will so advise MediciNova and submit a specification of its requirements to MediciNova. Within 10 working days of receiving the specification, MediciNova will provide Asahi with a cost and time estimate for performing the changed or
additional 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Page 4 of 14 

	 	 
Services. Any such additional Services, compensation and time schedules must be mutually agreed upon by the Parties in writing prior to the provision of said
Services in an amendment to the pertinent Project Addendum, and the Services set forth therein shall be deemed to be Services as the term is used in this Agreement. 

  

	4.	FINANCIAL ARRANGEMENTS 

  

	4.1.	Asahi will be responsible for the settlement of all amounts due to MediciNova in a form and of a nature reasonably acceptable to MediciNova. Each Project Addendum attached to this
Agreement will include a payment schedule for the performance of the Services. Payment of all invoices submitted by MediciNova to Asahi are due within 30 days of receipt of invoice by Asahi unless otherwise set forth in the Project Addenda. In the
event any Project Addendum, or this Agreement, is terminated, Asahi will pay MediciNova pursuant to the provisions of Section 11 of this Agreement. 

  

	4.2	Taxes (and any penalties thereon) imposed on any payment made by Asahi to MediciNova will be the responsibility of MediciNova. 

  

	4.3	MediciNova will provide all necessary fiscal management of its Suppliers, and will act as agent for Asahi in paying such Suppliers for the Services they provide. MediciNova will pay
the Suppliers directly and will be reimbursed by Asahi for such costs on a pass-through basis. Upon execution of each Project Addenda, Asahi will deposit with MediciNova an amount specified in the Project Addendum. Thereafter, MediciNova will
invoice Asahi for its Supplier fees, costs and expenses (collectively, the “Supplier Fees”) and its management fee in accordance with the payment terms of the Project Addendum. Asahi will pay such invoices in accordance with Section 4.1.

  

	5.	INTELLECTUAL PROPERTY RIGHTS AND ACCESS TO STUDY DATA 

  
 Ownership of the Know-How, Intellectual Property Rights relating to the Know-How and all other Intellectual Property Rights resides exclusively in Asahi
and/or its Affiliates. MediciNova agrees to assign and hereby assigns to Asahi and will require all of its Suppliers to agree to assign to Asahi all rights MediciNova or its Affiliates, directors, officers, employees, representatives or Suppliers
may have in any Know-How and Intellectual Property Rights and agrees to assist Asahi, at Asahi’s expense, in obtaining or extending protection and agrees to do any act or execute any document as may be required in order to enable ownership of
such rights to be vested in Asahi. MediciNova represents that it has and will continue to have agreements with its Affiliates, directors, officers, employees, agents, representatives and Suppliers to effectuate the terms of this Section and that it
will enforce such agreements to provide Asahi with the benefit of this Section. Notwithstanding the foregoing, Asahi acknowledges that MediciNova possesses certain inventions, processes, know-how, trade secrets, improvements, and other intellectual
properties and other assets including, but not limited to, analytical methods, procedures and techniques, procedure manuals, personnel data, financial information, computer technical expertise and software, which have been independently developed by

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Page 5 of 14 

 
MediciNova and which relate to MediciNova’s business or operations (collectively, “MediciNova Property”). Asahi and MediciNova agree that any
MediciNova Property or improvements thereto which are used, improved, modified, or developed by MediciNova under or during the term of this Agreement are the sole and exclusive property of MediciNova, provided that MediciNova will not, without
Asahi’s prior written consent, integrate MediciNova Property into any process or procedure such that future practice of the process or procedure would require a license to use such MediciNova Property. 
  

	5.1	Asahi will own and have the exclusive and unrestricted free right to use for all purposes the material, Documentation, data (including without limitation Study Data) and other
information of any kind generated or created as part of the Services; provided, however, that such exclusive unrestricted free right to use will not apply to the MediciNova Property. At all times during and following termination of this Agreement,
Asahi is entitled to make such use of, disclose and publish the Study Data, the Know-How and the Intellectual Property Rights as it sees fit. MediciNova may not publish any articles, make any presentations or disclose information in any way relating
to the Services or referring to data, information or materials generated as part of the Services, in whole or in part, without the prior written consent of Asahi. For the avoidance of doubt, Study Data, Know-How and Intellectual Property Rights are
all Client Information under Section 6 herein. 

  

	6.	MEDICINOVA HEREBY ACKNOWLEDGES AND AGREES FOR ITSELF AND ITS AFFILIATES THAT: 

  

	 	6.0.1 	nothing contained herein grants any right to MediciNova to use any trade marks or trade names of Asahi or its Affiliates relating to Asahi’s Compounds;

  

	 	6.0.2 	nothing contained herein grants any licence, right or permission to MediciNova to use the Know-How, Intellectual Property Rights, the Background IPR and other Client Information
except as specifically agreed herein. 

  

	6.1	Asahi hereby grants MediciNova and its Suppliers a non-exclusive, non-transferable, royalty-free licence to use the Background IPR for the purpose only and to the extent necessary
to enable MediciNova and its Suppliers to perform the Services under this Agreement. This licence automatically terminates upon the completion (or earlier termination) of the Services or termination of this Agreement. For the avoidance of doubt,
MediciNova or its Suppliers have no rights whatsoever to disclose, refer to, publish or use the Know-How, the Intellectual Property Rights or other Client Information, whether during or after termination of this Agreement, except as expressly set
out in this Agreement. 

  

	7.	CONFIDENTIALITY 

  

	7.1	The Confidentiality Agreement remains in full force and effect. 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Page 6 of 14 

	7.2	MediciNova will put in place similar agreements with its Suppliers. 

  

	8.	LIABILITY AND INDEMNITY 

  

	8.1	Each Party will indemnify and hold harmless the other Party, its Affiliates, directors, officers, employees and agents in respect of all liabilities, costs, claims, loss, damage,
demands, actions and expenses, including reasonable attorneys’ fees and expert costs and expenses, arising directly from the breaching Party’s material breach of any of the terms of this Agreement; provided, however, that the breaching
Party is not obligated under this provision for any indirect, special, incidental or consequential loss or damage. 

  

	8.2	The indemnities set out above do not apply to any claim or proceeding if and to the extent that such claim results from the fault or negligence of the Party seeking to benefit from
the indemnity, its employees or agents. 

  

	8.3	The Party seeking indemnification under this section (the “Indemnified Party”) shall (i) give the other Party (the “Indemnifying Party”) notice of the relevant
claim, (ii) cooperate with the Indemnifying Party, at the Indemnifying Party’s expense, in the defense of such claim, and (iii) give the Indemnifying Party the right to control the defense and settlement of any such claim, except that the
Indemnifying Party shall not enter into any settlement that affects the Indemnified Party’s rights or interest without the Indemnified Party’s prior written approval. The Indemnified Party shall have no authority to settle any claim on
behalf of the Indemnifying Party. 

  

	8.4	For the purposes of this clause, any Study investigator or Study staff retained to conduct the Study, on behalf of Asahi, are not deemed to be an agent or subcontractor of
MediciNova. 

  

	9.	RECORD KEEPING, INSPECTION, AND AUDIT 

  

	9.1	Asahi may, at any time during the continuance of this Agreement, inspect, examine, and audit at mutually agreed upon times the records, operating procedures, methods, facilities and
premises of MediciNova, its Suppliers and investigators solely to monitor the performance of the Services hereunder, to determine whether the Services are being conducted fully in accordance with the Project Addendum and all applicable laws and
regulations. Asahi may appoint an agent or agents to conduct any inspection, examination or audit under this clause on Asahi’s behalf. MediciNova will not make unreasonable objections to independent third party auditors selected by
Asahi. 

  

	9.2	 During the term of this Agreement and for a period of one year after, MediciNova or its Suppliers will maintain, and will be responsible for the storage
of, all materials and data obtained or generated by MediciNova or its Suppliers in the course of providing the Services, including all computerized records and files, in a secure area reasonably 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Page 7 of 14 

	 	 
protected from fire, theft and destruction. Project records, supplies and samples will be handled, stored and archived in a manner consistent with GMP, GCP,
GLP and similar international guidelines. The termination of this Agreement for whatever reason does not release MediciNova and its Suppliers from its obligations under any appropriate international guidelines. 

  
 Upon at least twenty days’ advance notice from Asahi, MediciNova will
make said records available to representatives or agents of Asahi in MediciNova’s offices for the purposes of auditing said records to verify MediciNova’s or its Suppliers’ compliance with the terms of this Agreement. 
  
 In the event information confidential to a third party is contained on any
records subject to audit by Asahi, such records may be reviewed by an independent auditor appointed by Asahi. Such independent auditor will sign in advance of inspection a confidential disclosure agreement suitable in form to Asahi, MediciNova, and
the appointed auditor. 
  

	10.	FORCE MAJEURE 

  
 If the performance of this Agreement or any obligation under it is prevented, restricted or interfered with by reason of circumstances beyond the
reasonable control of that Party obliged to perform it (including, without limitation, flood, fire, storm, strike, lockout, sabotage, terrorist act, civil commotion and government intervention), the Party so affected will (upon giving prompt notice
thereof to the other Party) be excused from performance to the extent only of the prevention, restriction or interference, provided always that the Party so affected will use its reasonable endeavours to avoid or remove the causes of non-performance
and will continue performance as expeditiously as possible as soon as such causes have been removed. In case the delay caused by Force Majeure exceeds one month the Parties will meet to discuss the situation, and the Party suffering from the
non-performance of the other party will have the right to terminate this Agreement. 
  

	11.	TERM AND TERMINATION 

  

	11.1	This Agreement will commence on the Effective Date and continue indefinitely unless earlier terminated in accordance with this Section 11. Project Addenda will commence upon the
date of complete execution by the Parties and will terminate upon the completion of Services unless earlier terminated in accordance with this Section 11. 

  

	11.2	 If either Party is in default of its material obligations under this Agreement, the non-defaulting Party will promptly notify the defaulting Party in writing of any
such default. The Parties will have a period of 30 days from the date of receipt of such notice within which to agree on a process to remedy such default. If the Parties fail to agree on appropriate reasonable action or if the defaulting Party is
unable to so remedy the default, 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Page 8 of 14 

	 	 
this Agreement will at non-defaulting Party’s option, immediately terminate upon notice in writing to the defaulting Party.

  

	11.3	Either Party may immediately terminate this Agreement or any or all Project Addenda upon notice in writing to the other Party if the other Party convenes a meeting of its creditors
or goes or threatens to go into liquidation (other than for the purposes of amalgamation or reconstruction), has an administration order made in relation to it or otherwise ceases to trade. 

  

	11.4	Either Party may immediately terminate a Project Addendum upon written notice to the other Party on the ground that the safety of the patients in a Study warrants termination.

  

	11.5	Asahi may terminate a Project Addendum immediately at any time upon written notice. 

  

	11.6	Either Party may terminate this Agreement at any time upon giving three month’s written notice to the other Party. 

  

	11.7	The termination of this Agreement by either Party shall automatically terminate any and all Project Addenda, unless otherwise specified. 

  

	11.8	Termination of this Agreement or a Project Addendum will not affect the accrued rights and liabilities of the Parties hereto. 

  

	11.9	In the event of termination of this Agreement or a Project Addendum, Asahi will reimburse MediciNova for work properly performed to date and make payments of monies outstanding upon
receipt of termination notice, and reimburse any reasonably incurred out of pocket expenses and non-cancellable obligations related to the Services, including without limitation all fees due to Suppliers and any termination fees or other charges
incurred by MediciNova as a result of the termination of services with Suppliers and all costs incurred for work that is in process at the time of termination including any costs to wind up such work in process. Tasks associated with termination
itself will only be performed by MediciNova upon request by Asahi, in which case Asahi will be liable for such costs. Provided, however, in the event of termination of this Agreement or a Project Addendum for reasons other than default by
MediciNova, Asahi will pay MediciNova an amount equal to the management fee earned by MediciNova up to the date of termination. 

  

	11.10 	Clauses that by their nature should survive, will survive termination of this Agreement or of a Project Addendum. 

  

	12.	DISPUTE RESOLUTION 

  

	12.1	 Any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be finally settled by arbitration. If the respondent in such
arbitration is MediciNova, the arbitration shall be held in San Diego, California in accordance with the 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Page 9 of 14 

	 	 
commercial arbitration rules of the American Arbitration Association. If the respondent in such arbitration is Asahi, the arbitration shall be held in Tokyo,
Japan in accordance with the commercial arbitration rules of the Japan Commercial Arbitration Association. Judgment upon the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof. 

 

	13.	NOTICES 

  
 Any notice or other document to be given under this Agreement will be in writing and will be deemed to have been duly given if sent by first class post,
registered post, internationally recognized overnight courier, or facsimile (provided in the latter case that a confirmatory copy is sent by post on the same day) to a Party at the address or facsimile number set out below or such other address as a
Party may from time to time designate by written notice to the other Parties: 
  

			
	for Asahi	 	for MEDICINOVA
		
	 Akio Kobayashi/ General Manager
 Pharmaceuticals Division
 Asahi Kasei Pharma Corporation
 9-1, Kanda Mitoshiro-cho, Chiyoda-ku,
 Tokyo 101-8481 Japan
	 	 Takashi Kiyoizumi, M.D., Ph.D.
 MediciNova, Inc
 4350 La Jolla Village Drive
 - Suite 950
 San Diego, CA 92122
 USA

		
	 Phone: (3) 3259 5776
	 	 Phone: (858) 373 1200

	 Fax : (3) 3259 5741
	 	 Fax: (858) 373 7000

  

	14.	GENERAL PROVISIONS 

  

	14.1.	No change, modification, extension or amendment of the Agreement or any Project Addendum are valid and enforceable unless made in writing and agreed by both Parties.

  

	14.2	If any one or more provisions of this Agreement is found to be illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions will
not in any way be affected or impaired thereby, provided the surviving Agreement materially comports with the Parties’ original intent. 

  

	14.3	This Agreement plus any relevant addenda attached hereto and the Confidentiality Agreement constitute the entire agreement between the Parties as to the subject matter hereof and
supersedes and overrides all prior agreements, discussions, representations and understandings relating to the same subject matter. 

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Page 10 of 14 

	14.4	The Parties hereto are independent contractors and nothing in this Agreement will create or be construed as creating a partnership or a relationship of agent and principal between
the Parties, except as specifically described in this Agreement. 

  

	14.5	The validity, performance, construction, and termination of this Agreement will be governed by and construed in accordance with the Laws of the state of California.

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Page 11 of 14 

 IN WITNESS WHEREOF this Agreement has been executed by duly authorised officers of the Parties. 
  

					
	For: Asahi Kasei Pharma Corporation	 	 	 	For: MediciNova, Inc.
			
	 /s/ Yasuaki Nakaoka
	 	 	 	 /s/ Takashi Kiyoizumi

	(Signature)	 	 	 	(Signature)
			
	Yasuaki Nakaoka	 	 	 	Takashi Kiyoizumi, M.D., Ph.D.
	(Print Name)	 	 	 	(Print Name)
			
	President	 	 	 	Chief Executive Officer
	(Title)	 	 	 	(Title)
			
	February 16, 2004	 	 	 	 
	(Date)	 	 	 	(Date)

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Page 12 of 14 

  
 Master Service Agreement
between Asahi Kasei Pharma, Corp. (ASAHI) and MediciNova, Inc. 
 (MEDICINOVA) 
  
 Addendum 1 
  
 [**] is approved for the prevention of [**]. [**] is an orally
available, [**] that is approved in Japan, Korea and China for the prevention of [**]. It is a [**]. The compound was isolated from a culture medium of the mold [**] in the laboratories of ASAHI, subsequently developed
and launched as [**] in Japan (1984). 
  
 [**] , although primarily
isolated as a substance having [**], was found to [**]. 
  
 In
contrast to other [**], [**] has been shown in animal experiments to [**]. 
  
 In addition to the above mentioned prevention [**], [**] has been approved in Japan for the treatment of [**]. 
  
 To further the clinical utility of [**], ASAHI wishes to explore [**]. As a first step towards this goal, additional Phase I
safety testing is necessary prior to an evaluation of [**]. 
  
 MEDICINOVA
will provide the following services to ASAHI in support of a single Phase I trial of [**] : 
  
 CRO audit and selection 
 CRO contract negotiation 
 Investigator’s Brochure review 
 CMC review 
 Review analytical methods/validation 
 Protocol & Informed Consent design & review 
 Maintain a regulatory document file 
 Coordinate CTM delivery 
 Clinical trial monitoring 
 Coordinate pharmacokinetics sample delivery

 Periodic safety review 
 Review/edit final study report

  
 These services will be performed by, or under the direct supervision of, Dr.
Kenneth W. Locke, Sr. VP, Development Operations & Drug Discovery of MEDICINOVA Completion of the above services, excluding the review/editing of the final report, will be completed no later than May 1, 2004. 
  
 In consideration for these services, ASAHI agrees to pay MEDICINOVA monthly within 30 days of
the receipt of the invoice from MEDICINOVA. The hourly rate of MEDICINOVA fee is USD[**]. It is expected that the aggregated required hours for the service is less than [**] hours. 
  
 The above consideration does not include CRO costs for conduct of the study,
product-associated costs, analysis of plasma/serum samples or interpretation of pharmacokinetic study results, incidental costs (e.g., any shipping charges or tariffs/duties) or travel costs incurred by MEDICINOVA in the course of conducting the
Phase I study. All such charges are the responsibility of ASAHI and are payable in U.S. dollars within 30 days of invoice by MEDICINOVA. 
  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Page 13 of 14 

					
	for ASAHI KASEI PHARMA, CORP.	 	 	 	for MEDICINOVA, INC.
			
	 /s/ Yasuaki Nakaoka
	 	 	 	 /s/ Takashi Kiyoizumi

	 Yasuaki Nakaoka, President
 Asahi Kasei Pharma Corporation
 9-1 Kanda Mitoshiro-cho,
 Chiyoda-ku,
 Tokyo 101-8481
 Japan
	 	 	 	 Takashi Kiyoizumi, M.D., Ph.D.
 MediciNova, Inc.
 4350 La Jolla Village Drive -
 Suite 950
 San Diego, CA 92122
 USA

	 Phone: (3)-3259-5776
	 	 	 	 Phone: (858) 373-1200

	 Fax : (3)-3259-5741
	 	 	 	 Fax: (858) 373-7000

  

	**	CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Page 14 of 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}]]